Correlation Between Krebs Biochemicals and Nucleus Software

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Krebs Biochemicals and Nucleus Software at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Krebs Biochemicals and Nucleus Software into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Krebs Biochemicals and and Nucleus Software Exports, you can compare the effects of market volatilities on Krebs Biochemicals and Nucleus Software and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Krebs Biochemicals with a short position of Nucleus Software. Check out your portfolio center. Please also check ongoing floating volatility patterns of Krebs Biochemicals and Nucleus Software.

Diversification Opportunities for Krebs Biochemicals and Nucleus Software

0.09
  Correlation Coefficient

Significant diversification

The 3 months correlation between Krebs and Nucleus is 0.09. Overlapping area represents the amount of risk that can be diversified away by holding Krebs Biochemicals and and Nucleus Software Exports in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nucleus Software Exports and Krebs Biochemicals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Krebs Biochemicals and are associated (or correlated) with Nucleus Software. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nucleus Software Exports has no effect on the direction of Krebs Biochemicals i.e., Krebs Biochemicals and Nucleus Software go up and down completely randomly.

Pair Corralation between Krebs Biochemicals and Nucleus Software

Assuming the 90 days trading horizon Krebs Biochemicals and is expected to generate 3.77 times more return on investment than Nucleus Software. However, Krebs Biochemicals is 3.77 times more volatile than Nucleus Software Exports. It trades about 0.31 of its potential returns per unit of risk. Nucleus Software Exports is currently generating about -0.25 per unit of risk. If you would invest  8,095  in Krebs Biochemicals and on August 29, 2024 and sell it today you would earn a total of  3,639  from holding Krebs Biochemicals and or generate 44.95% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Krebs Biochemicals and  vs.  Nucleus Software Exports

 Performance 
       Timeline  
Krebs Biochemicals and 

Risk-Adjusted Performance

12 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Krebs Biochemicals and are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak fundamental drivers, Krebs Biochemicals demonstrated solid returns over the last few months and may actually be approaching a breakup point.
Nucleus Software Exports 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Nucleus Software Exports has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Krebs Biochemicals and Nucleus Software Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Krebs Biochemicals and Nucleus Software

The main advantage of trading using opposite Krebs Biochemicals and Nucleus Software positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Krebs Biochemicals position performs unexpectedly, Nucleus Software can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nucleus Software will offset losses from the drop in Nucleus Software's long position.
The idea behind Krebs Biochemicals and and Nucleus Software Exports pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Complementary Tools

Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules